S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
A case report and review of the literature
Chu Zhang, MD, PhD, Guang-Mao Yu, MD, Miao Zhang, MD, Dong Liu, MD.

Abstract
Rationale: Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer. To date, studies on apatinib plus S-1 as first-line palliative therapy for metastatic gastroesophageal junction (GEJ) cancer are rare.

Patient concerns: A 61-year-old female patient was admitted with dysphagia, significant loss of body weight, and poor performance status.

Diagnoses: Endoscopic biopsy revealed the diagnosis of poorly-differentiated GEJ adenocarcinoma, and the patient was clinically staged as T3NxM1G3 (IVB).

Interventions: She had received 4 cycles of palliative therapy using oral apatinib (425 mg daily) plus S-1 (40 mg twice daily for 4 weeks, with a 2-week drug-free interval), followed by maintenance low-dose apatinib (250 mg daily) plus S-1 at the same dosage thereafter.

Outcomes: Her progression-free survival was nearly 5 months, and the overall survival was >11 months up to now. The adverse events were tolerable.

Lessons: Apatinib plus S-1 might be an alternative option for late-stage GEJ cancer. However, high-quality trials are warranted before the recommendation of this therapeutic regimen.

Abbreviations: AEs = adverse events, CT = computed tomography, DCR = disease control rate, ECOG = Eastern Cooperative Oncology Group, GEJ = gastroesophageal junction, MRI = magnetic resonance imaging, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, PR = partial response, RECIST 1.0 = response evaluation criteria in solid tumors version 1.0, SD = stable disease, TKI = tyrosine kinase inhibitor, VEGF = vascular endothelial growth factor, VEGFR-2 = vascular endothelial growth factor receptor 2.

Keywords: angiogenesis inhibitor, apatinib, chemotherapy, S-1, targeted therapy, vascular endothelial growth factor receptor

1. Introduction
Gastric cancer is the fifth most common malignancy and the third leading cause of cancer mortality worldwide,[1] and the majority of the patients are diagnosed as advanced disease on admission. Palliative therapy in addition to best supportive care for stage IV gastric or esophageal cancer patients with poor performance status is aimed at providing a survival benefit or improved quality of life, however, the optimal first-line therapeutic regimen remains controversial.

Apatinib, a small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could be considered as a third-line option for refractory gastric or gastroesophageal junction (GEJ) cancer.[5] To date, the evidence regarding the combined use of apatinib and S-1 as first-line treatment for metastatic GEJ adenocarcinoma is insufficient. Herein we present a case of late-stage, poorly-differentiated GEJ adenocarcinoma in which the diffused liver metastases shrank and maintained stable for half a year since the administration of S-1 plus apatinib.

2. Case presentation
The clinical data of this patient was treated anonymously for privacy concern. A 61-year-old woman was admitted on January...
21, 2019 because of abdominal pain and black stool since November 2018, after experiencing dysphagia and weight loss of nearly 10kg over the preceding 6 months. Her previous medical history was unremarkable. Physical examination showed emaciation and a noticeably enlarged abdomen, with a body mass index (BMI) of 19.0. Besides, laboratory tests indicated mainly normal blood cell counts, renal function, neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 724, and cytokeratin-19 fragment (CYFRA 21-1) but decreased serum hematocrit (19.3%, normal range 35–45%), hemoglobin (53g/L, normal range 110–150g/L), and albumin (31.5g/L, normal range 35–55g/L), followed by elevated CA125 (629.2U/ml, normal range 0–35 U/ml). Additionally, impaired hepatic function as indicated by elevated serum aspartate aminotransferase (AST) (175.0U/L, normal range 1–40U/L), alanine aminotransferase (ALT) (56.0U/L, normal range 1–40U/L), alkaline phosphatase (ALP) (248U/L, normal range 15–140 U/L), gamma-glutamyl transpeptidase (GGT) (103U/L, normal range 0–60U/L), and lactic dehydrogenase (LDH) (1692U/L, normal range 15–210U/L). Therefore, cachexia was diagnosed as her estimated Eastern Cooperative Oncology Group (ECOG) score was 3 due to her impaired nutrition and performance status, and best supportive care was administered initially.

On January 22, 2019, the gastric endoscopy and abdomen computed tomography (CT) scan revealed primary lesions in the lower esophageal region and in the cardiac end of the stomach. Further contrast-enhanced CT revealed irregularly thickened gastroesophageal junction (GEJ) wall, tumor-infiltrated adventitia, extensive distant metastasis (left supraclavicular and mediastinal lymph nodes), peritoneal effusion, and significantly enlarged liver with diffused metastases between the liver and stomach (Fig. 1). In addition, a pulmonary lesion located in the left upper lobe were also indicated (Fig. 2).

Endoscopic biopsy revealed the diagnosis of poorly-differentiated GEJ adenocarcinoma, and further immunohistochemistry stain of the specimen showed positive human epidermal growth factor receptor 2 (HER-2) and vascular endothelial growth factor (VEGF). Other metastasis was excluded using cranial magnetic resonance and whole-body bone emission CT. Then she was staged as cT3Nxm1G3 (IVB) according to the 8th edition of tumour, node and metastasis (TNM) staging system for esophageal cancer.[13]

After a multidisciplinary evaluation, first-line palliative oral apatinib (425mg, daily) plus S-1 (40mg twice daily for 4 weeks, with a 2-week drug-free interval, as her body surface area was <1.5 m²) was administered for this patient. Informed consent was obtained from the patient prior to treatment. During the treatment, CT scans and serum CA125 were conducted irregularly for efficacy evaluation in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), meanwhile, the treatment-related side effects were recorded as National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Encouragingly, the GEJ tumor and the hepatic lesions showed stable disease (SD) and partial response (PR) respectively after 1 cycle of therapy using apatinib plus S-1, nevertheless, these tumors maintained SD after another 3 cycles of treatment without dosage reduction of the 2 agents (Fig. 1). In addition, the pulmonary lesion demonstrated a complete remission after 2 cycles of treatment (Fig. 2), although a pathological diagnosis was not obtained, because a CT-guided biopsy of this lesion was not performed with the aim to diminish unnecessary injury to the patient. Meanwhile, the serum CA125 was decreased steadily as shown in Fig. 3. Grade 2/3 toxicities including hypertension and hand-foot syndrome were tolerable after proper treatment. No grade 4 adverse event was observed in this case.

On July 4, 2019, the patient showed improved status as her ECOG score was 1. Although the hepatic lesions remained SD, the GEJ tumor was noticeably thickened (Fig. 1F). However, the patient refused docetaxel and oxaliplatin as second-line therapy and continued to take low-dose apatinib (250mg, daily) and S-1
perspective study does not support the survival benefit of S-1 plus cisplatin over S-1 monotherapy in advanced or recurrent GC patients aged ≥70 years.\(^3\) Paclitaxel plus S-1 shows a lower progression-free survival rate as compared to paclitaxel plus fluorouracil.\(^6\) Additionally, it is reported that S-1-containing regimens could not improve the survival but increase the hematological toxicities in Asian patients as compared with 5-FU-containing regimens.\(^7\) As a consequence, a biweekly S-1 regimen might be considered in GC patients to diminish gastrointestinal and hematological toxicities.\(^8\)

Tumor angiogenesis plays an important role in cancer metastasis, however, only very few approved agents lead to a clinical improvement in metastatic GC patients.\(^9\) Apatinib significantly improves the OS and PFS in metastatic gastric or GEJ cancer patients who are refractory to ≥2 lines of prior chemotherapy, and the most common grade 3/4 adverse events are hand-foot syndrome, proteinuria, and hypertension.\(^10\) A meta-analysis of randomized controlled trials reveals the significant efficacy and safety of VEGFR-2 inhibitors in metastatic gastric and GEJ cancer patients.\(^11\) Another network meta-analysis shows that apatinib, regorafenib, and rilotumumab improve the PFS and OS of advanced GC patients.\(^12\) Furthermore, apatinib can modulate the tumor immunosuppressive microenvironment, which is associated with the treatment resistance to programmed cell death protein 1 (PD-1) inhibitors.\(^13\) Further studies of anti-angiogenic therapy combined with chemotherapy or immune checkpoint inhibitors provide hope for GC patients. The addition of apatinib (500 mg/d) to chemotherapy could further improve the PFS of metastatic GEJ adenocarcinoma patients refractory to prior chemotherapy.\(^14\)

It is noteworthy that, high-quality studies assessing the efficacy of apatinib plus S-1 in advanced gastric or esophageal cancer remain scarce. A meta-analysis of the reports published in Chinese language indicates that S-1 plus apatinib shows a favorable efficacy in GC patients as compared with S-1 alone,\(^15\) but it can be difficult to draw reliable conclusions due to the low quality of these included studies. The registered trials evaluating the efficacy of S-1 plus apatinib for gastric or gastroesophageal cancer are listed in Table 1, as better evidence are necessary before the incorporation of this regimen into practice guidelines.

Anti-angiogenic strategy has major practical limitations such as inevitable resistance, and there are no definitive biomarkers for apatinib in GC.\(^16\) To the best of our knowledge, there is only one case report in English language, which shows that first-line apatinib plus S-1 in metastatic GC is effective based on peripheral circulating tumor cell monitoring.\(^17\) As for the presented case,

| Registration identifier | Disease | Treatment line | Estimated enrollment | Primary outcomes | Status | Country |
|------------------------|---------|----------------|----------------------|-----------------|--------|---------|
| ChiCTR-1900021412      | AGC after D2 radical resection | Adjuvant        | 36                   | DFS             | Recruiting | China   |
| ChiCTR1800018854       | Advanced stomach or GEJ cancer | First-line      | 242                  | PFS, OS         | Recruiting | China   |
| ChiCTR-OPC-17013262    | Adenocarcinoma of the stomach or GEJ | First-line neoadjuvant | 50            | PFS             | Recruiting | China   |
| ChiCTR-IRJ-17010609    | AGC     | First-line     | 35                   | PFS             | Recruiting | China   |
| ChiCTR-OPC-16010061    | GC      | Neoadjuvant    | 30                   | Safety, R0 rate | Recruiting | China   |
| ChiCTR-OH-17012822     | Advanced ESCC | Exploratory | 34                   | PFS, OS         | Recruiting | China   |
| NCT02592678            | AGC     | Conversion therapy | 30                 | R0 rate         | Recruiting | China   |
| NCT03950141            | HER2(+) AGC | Maintenance therapy | 30           | PFS             | Recruiting | China   |
| NCT03271073            | AGC     | Second-line and beyond | 20            | PFS             | Recruiting | China   |
| NCT03276156            | AGC     | Maintenance therapy | 12            | PFS, AEs        | Recruiting | China   |
| NCT031800020061        | AGC and GEJ cancer | Maintenance therapy | 30            | PFS             | Not yet recruiting | China   |
| NCT031800016932        | AGC     | First-line     | 30                   | PFS, OS         | Not yet recruiting | China   |
| NCT02525237            | AGC     | First-line     | 30                   | PFS, AEs        | Not yet recruiting | China   |
| NCT0192735             | AGC     | Neoadjuvant    | 50                   | R0 rate         | Recruiting | China   |

\(\text{AEs} = \text{adverse events}, \ AGC = \text{advanced gastric cancer}, \ ESCC = \text{esophageal squamous cell carcinoma}, \ GC = \text{gastric cancer}, \ GEJ = \text{gastroesophageal junction}, \ HER2 = \text{human epidermal growth factor receptor 2}, \ OS = \text{overall survival}, \ PFS = \text{progression-free survival}, \ R0 = \text{microscopic tumor clearance}\)
favorable oncological outcome was achieved as she gained a 5-month PFS and 11 months of OS after the administration of concurrent apatinib and S-1, however, acquired resistance appeared after 4 cycles of treatment.

On the other hand, because of the heterogeneous nature of GC, it is not possible to evaluate a standard therapeutic approach. The addition of anti-VEGF agents to chemotherapy significantly improve the OS of advanced GC patients when compared with chemotherapy alone. But there is still no conclusive agreement on how to combine anti-angiogenic agents with other regimens to get prime effects. The most widely accepted first-line chemotherapy regimen for advanced GC is the combination of platinum and fluoropyrimidine, and trastuzumab could be considered if the tumor harbors positive human epidermal growth factor receptor type 2 (HER2). Furthermore, trastuzumab plus S-1 demonstrates promising activity in elderly HER2-positive, advanced GC patients, however, the optimal second- and third-line therapy is still a matter of debate. Ramucirumab plus taxane is the optimal second-line treatment, followed by taxane or irinotecan monotherapy as alternatives. Moreover, apatinib monotherapy is preferred in third-line setting, although apatinib shows modest antitumor activity.

From this report, two questions arise: How to conquer acquired resistance of S-1 plus apatinib? What is optimal duration of S-1 plus apatinib as first-line palliative chemotherapy? To answer these questions, more researches are needed.

4. Conclusions
Oral S-1 plus apatinib might be a reasonable first-line palliative option for late-stage GEJ adenocarcinoma patients with compromised performance status, however, high-quality trials are warranted.

Author contributions
Conceptualization: Chu Zhang, Dong Liu.
Data curation: Guang-Mao Yu.
Funding acquisition: Miao Zhang.
Methodology: Dong Liu.
Resources: Dong Liu.
Writing – original draft: Chu Zhang, Guang-Mao Yu.
Writing – review & editing: Chu Zhang, Miao Zhang, Dong Liu.
Chu Zhang orcid: 0000-0001-5860-8300.
Guang-Mao Yu orcid: 0000-0002-1737-9243.
Miao Zhang orcid: 0000-0001-7431-5986.
Dong Liu orcid: 0000-0003-2071-4548.

References
[1] Torrec LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
[2] Aoyama T, Yoshikawa T. Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol 2016;13:268-70.
[3] D’Journo XB. Clinical implication of the innovations of the 8(th) edition of the TNM classification for esophageal and esophago-gastric cancer. J Thorac Dis 2018;10(suppl 22):S2671-81.
[4] Sanford M, S-1 (Teysumo(R)): a review of its use in advanced gastric cancer in non-Asian populations. Drugs 2013;73:3845-55.
[5] Makiyama A, Kunieda K, Noguchi M, et al. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer 2018;21:792-801.
[6] Liu H, Chen X, Sun J, et al. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus S-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2014;93:e164.
[7] Chen XD, He FQ, Chen M, et al. Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3916.
[8] Xiao C, Qian J, Zheng Y, et al. A Phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. Medicine (Baltimore) 2019;98:e15696.
[9] Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett 2016;372:187-91.
[10] Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophagal junction. J Clin Oncol 2016;34:1448-54.
[11] Roviello G, Polom K, Roviello F, et al. Targeting VEGFR-2 in metastatic gastric cancer: results from a literature-based meta-analysis. Cancer Invest 2017;35:1879-94.
[12] Zhao TT, Xu H, Xu HM, et al. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials. Gastric Cancer 2018;21:361-71.
[13] Zhao S, Ren S, Jiang T, et al. Low-Dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-1 blockade in lung cancer. Cancer Immunol Res 2019;7:630-43.
[14] Guo Y, Tang J, Huang XE, et al. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: a prospective clinical study. Medicine (Baltimore) 2019;98:e13908.
[15] Liu Y, Zhou C, Zhang K, et al. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97:e13529.
[16] Procacci L, Damuzzo V, Di Sarra F, et al. Safety and tolerability of antiangiogenic protein kinase inhibitors and vascular-disrupting agents in cancer: focus on gastrointestinal malignancies. Drug Saf 2019;42:159-79.
[17] Chen W, Yu J, Zhang Y, et al. First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report. Ann Transl Med 2019;7:181.
[18] Mawalla B, Yuan X, Luo X, et al. Treatment outcome of anti-angiogenic therapy in patients with advanced gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes 2018;11:21.
[19] Yang L, Wang X, Wang B, et al. The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: a meta-analysis and systematic review. Medicine (Baltimore) 2018;97:e12789.
[20] Endo S, Kurokawa Y, Gamoh M, et al. Advanced gastric cancer: a systematic review of the literature. Cancer Metastasis Rev 2016;35:439-46.
[21] Kimura Y, Fujii M, Masushi T, et al. Multicenter phase II study of trastuzumab plus S-1 in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer 2018;21:421-7.
[22] Ter Veer E, Haj Mohammad N, van Valkenhoef G, et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Rev 2016;35:439-56.
[23] Mizrahi Kaya D, Harada K, Shimodaira Y, et al. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol 2017;10:263-71.
[24] Chen LT, Oh DY, Ryu MH, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat 2017;49:851-68.
[25] Pasini F, Fraccon AP, Modena Y, et al. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer 2017;20:31-42.